Rosemary Laird, MD
Geriatric Medicine · Viera, FLNPI 1407856131
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 30.5% of the total. 2025 is the largest year on record at $22,323, more than ten times the $17 reported in 2019. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $574.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$20K
- Eli Lilly$19K
- Biogen$12K
- Novo Nordisk$9K
- E.r. Squibb & Sons, L.L.C.$2K
- Eisai Inc.$1K
- plus $1K from 4 others
Across 167 payments — averaging $37,949 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4.1M
- AbbVie$1.2M
- Braintree Laboratories, Inc.$715K
- E.r. Squibb & Sons, L.L.C.$150K
- Janssen Research & Development, LLC$143K
- Bristol Myers Squibb$11K
- plus $2K from 1 others
What the payments were for
- Consulting fees$35,56555%
- Speaking & faculty fees$17,20627%
- Travel & lodging$8,88614%
- Food & beverage$2,7084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $19,644 |
| Eli Lilly | 26 | $19,101 |
| Biogen | 14 | $11,801 |
| Novo Nordisk | 7 | $9,271 |
| E.r. Squibb & Sons, L.L.C. | 17 | $1,983 |
| Eisai Inc. | 13 | $1,359 |
| Merck | 7 | $999 |
| Genentech USA, Inc. | 1 | $150 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $42 |
| CMP Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$14,145
How this compares
$64,366 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 50 | $1,088 |
| Escitalopram Oxalate | 46 | $573 |
| Donepezil Hcl | 41 | $556 |
| Quetiapine Fumarate | 26 | $454 |
| Sertraline Hcl | 29 | $176 |
Paid to pharmacies, not to this prescriber.
Other geriatric medicine in Viera
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
- Jason StibichBrandon$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.